Gene Logic to Help Solvay Pharma Reposition Failed Rxs | GenomeWeb
NEW YORK (GenomeWeb News) — Gene Logic today said it will help Solvay Pharmaceuticals identify alternative development paths for multiple undisclosed drug candidates.
 
All of these drug candidates were discontinued or de-prioritized in clinical trials for reasons other than safety.
 
Terms of the deal call for Gene Logic to pocket milestone and royalty payments similar to those paid for development-stage in-licensing deals, discounted for the fact that Solvay originally identified the compounds.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.